Popular Articles
Stretch Mark Remedies

Six Researchers To Receive Prestigious Awards From The American Society Of Hematology
The American Society of Hematology (ASH), the world"s largest professional society of blood specialists, will honor six scientists who have made significant contributions to the understanding of hematologic diseases. These awards, including the newly created Ernest Beutler Lecture and Prize, will be presented at the 51st ASH Annual Meeting taking place December 5-8 in New Orleans.
generic viagra online
Elan And Transition Therapeutics Announce Phase 1 Data Showing ELND005 Achieves Desired Concentrations In Brain Tissue And Cerebrospinal Fluid
Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics Inc. (TSX: TTH, NASDAQ: TTHI) today presented Phase 1 data demonstrating that treatment with ELND005 (scyllo-inositol formerly known as AZD-103), achieves desired concentrations in human brain tissue and cerebrospinal fluid when given orally. Preclinical data also were presented showing that ELND005 administration is associated with preservation of choline acetyltransferase (ChAT), reflecting preservation of nerve cells that are critical to memory function in the brain. ELND005 is an orally-administered drug candidate in Phase 2 trials for the treatment of mild to moderate Alzheimer"s disease. These results were presented at the 2009 Alzheimer"s Association International Conference on Alzheimer"s Disease (ICAD 2009) in Vienna, Austria.
News of the day
LSUHSC Research On How Like Cell Receptor Systems Determine Very Different Functions, Supported By Grant
Andy Catling, PhD, Associate Professor in the Department of Pharmacology and the Stanley S. Scott Cancer Center at LSU Health Sciences Center New Orleans, has been awarded a $177, 500 supplement to his RO1 grant by the National Institute of General Medical Sciences to support his research on the mechanism by which seemingly similar cell receptor systems determine quite different functions influenced by hormones and drugs.
Health Insurance

Hospital Trust Recruiting For Trials Of New Flu Vaccine, UK

Southampton"s university hospitals are to take part in clinical trials of a vaccine that could protect against numerous types of flu - including pandemics such as bird and swine flu. Existing vaccines target only the outside of the flu virus, which frequently changes and varies in different strains of the virus, meaning new vaccines are needed each year. Novel new T-cell vaccines target the internal core of the flu viruses, which do not change very much over time or between strains. The study is being conducted by research staff and clinicians based at the Wellcome Trust Clinical Research Facility (WTCRF) at Southampton General Hospital and the Jenner Institute at Oxford University. "The current approach to tackling flu via the coat of the virus is not adequate because strains are constantly changing, new formulas have to be developed at short notice and then people are only protected for that particular strain," said Dr Saul Faust, director of the WTCRF in Southampton. "If successful, this new type of vaccine that targets the inside of the virus, as opposed to the shell, could potentially offer protection against many different strains of influenza A, including those that cause pandemics." Dr Faust, a specialist in infectious diseases, added: "Such an advanced vaccine would be suitable for all ages at any time of year and, as the substance of the vaccination would not change from year to year, there would be no need for annual injections." Three hundred healthy volunteers aged between 18 and 45 are required to take part. Initially, volunteers will have a blood test to see if they are immune to a particular strain of flu and 26 people who do not have this immunity will then go ahead to trial the new vaccine in the second part of the study. Southampton University Hospitals NHS Trust


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):